AstraZeneca had a pretty rough few years of R&D setbacks and failures up until 2012, when its former chief, David Brennan, was all but pushed out as a result. But things seem to have steadied somewhat since Pascal Soriot took the helm.
The FDA has rejected AstraZeneca’s hyperkalemia drug ZS-9 for the second time in 12 months. The news marks a further blow for a program AstraZeneca saw giving it a sizable share of a $6 billion (€5.5 billion) market when it acquired the asset in its $2.7 billion buyout of ZS Pharma.
Held up last year at the FDA by manufacturing issues, AstraZeneca has been granted a much-needed recommendation from the EMA for its $2.7 billion hyperkalemia drug ZS-9, now known (in Europe at least) as Lokelma (sodium zirconium cyclosilicate).
After a year of takeover rumors that seemed to fizzle out into nothing, Relypsa has finally found its match in the biotech’s drug marketing partner and Swiss healthcare company Galenica, which will buy the company for $1.53 billion.